开立医疗(300633) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 479,333,865.45, representing a 1.33% increase compared to CNY 473,030,518.35 in the same period last year[5]. - Net profit attributable to shareholders decreased by 27.65% to CNY 100,190,827.63 from CNY 138,474,386.29 year-on-year[5]. - Basic earnings per share fell by 28.12% to CNY 0.2326 from CNY 0.3236 in the same period last year[5]. - Total revenue for Q1 2024 reached ¥479,333,865.45, a slight increase from ¥473,030,518.35 in Q1 2023, representing a growth of approximately 0.6%[16]. - Net profit for Q1 2024 was ¥100,190,827.63, down from ¥138,474,386.29 in Q1 2023, reflecting a decrease of approximately 27.6%[17]. - Total comprehensive income for the first quarter was CNY 101,853,099.67, a decrease from CNY 137,850,777.52 in the previous year, representing a decline of approximately 26%[18]. - Basic earnings per share for the quarter were CNY 0.2326, down from CNY 0.3236 in the same period last year, reflecting a decrease of about 28%[18]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -28,513,064.73, a decline of 159.07% compared to CNY 48,269,069.80 in the previous year[5]. - Cash inflow from financing activities totaled CNY 25,933,220.00, an increase of 178.70% year-on-year[8]. - The company's cash flow from investing activities was negative at CNY -72,622,300.00, a decrease of 257.7% compared to the previous year[8]. - Cash and cash equivalents at the end of the period increased to CNY 1,851,932,314.08, up from CNY 1,485,916,653.31 at the end of the previous year, marking an increase of approximately 24.6%[21]. - Cash inflow from financing activities totaled CNY 259,332,185.06, significantly higher than CNY 93,051,792.00 in the previous year, indicating an increase of about 178%[21]. - The company reported a net increase in cash and cash equivalents of CNY 126,702,284.38 for the quarter, compared to CNY 163,767,322.18 in the previous year, a decrease of approximately 22.6%[21]. Assets and Liabilities - Total assets increased by 7.22% to CNY 4,043,654,290.12 from CNY 3,771,417,094.83 at the end of the previous year[5]. - Current liabilities rose to ¥731,634,034.53, compared to ¥568,624,898.28 in the previous year, an increase of about 28.6%[16]. - Total liabilities increased to ¥787,305,897.40 from ¥625,463,443.55, indicating a rise of approximately 25.8%[16]. - Non-current assets totaled ¥1,169,845,867.79, up from ¥1,146,021,099.31 in the previous year, marking an increase of about 2.6%[16]. - Total current assets increased to ¥2,873,808,422.33 from ¥2,625,395,995.52, representing a growth of approximately 9.5%[13]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,272, with the top two shareholders, Chen Zhiqiang and Wu Kunxiang, each holding 22.23% of shares[9]. - The total number of shares held by the top ten shareholders accounts for a significant portion of the company's equity, with the largest shareholders being natural persons[10]. - The company is actively managing its shareholder structure, with significant stakes held by institutional investors[10]. - The company has pledged shares amounting to 6,530,000 and 8,100,000 for Chen Zhiqiang and Wu Kunxiang respectively[9]. Expenses - The company’s management expenses rose by 37.34% to CNY 34,545,500.00 compared to the same period last year[7]. - Research and development expenses for Q1 2024 were ¥101,637,595.01, up from ¥80,009,904.74 in Q1 2023, indicating a growth of approximately 27%[17]. Other Financial Metrics - The company reported a government subsidy of CNY 10,209,304.60 included in non-recurring gains and losses[6]. - The company received CNY 35,937,349.84 in tax refunds, down from CNY 45,780,542.28 in the previous year, a decrease of about 21.5%[20]. - The company’s investment income received was CNY 17,769.69, a significant drop from CNY 4,065,963.94 in the previous year, indicating a decline of about 99.6%[20]. - Total operating costs for Q1 2024 were ¥394,005,611.99, compared to ¥358,549,235.76 in Q1 2023, indicating an increase of about 9.9%[17].